IDEAYA Biosciences, Inc. (FRA:30J)

IDEAYA Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	218.71	7	23.39	50.93	27.94
Revenue Growth (YoY)	3024.43%	-70.07%	-54.09%	82.28%	43.01%
Cost of Revenue	314.7	294.67	129.51	89.54	58.16
Gross Profit	-95.99	-287.67	-106.12	-38.61	-30.22
Selling, General & Admin	63.32	39.3	28.31	23.9	20.05
Operating Expenses	63.32	39.3	28.31	23.9	20.05
Operating Income	-159.31	-326.98	-134.43	-62.5	-50.27
Interest & Investment Income	35.64	29.27	9.92	3.15	2.34
EBT Excluding Unusual Items	-123.67	-297.71	-124.51	-59.35	-47.93
Gain (Loss) on Sale of Investments	9.98	23.23	11.55	0.7	-1.83
Pretax Income	-113.7	-274.48	-112.96	-58.66	-49.76
Net Income	-113.7	-274.48	-112.96	-58.66	-49.76
Net Income to Common	-113.7	-274.48	-112.96	-58.66	-49.76
Shares Outstanding (Basic)	88	82	58	41	35
Shares Outstanding (Diluted)	88	82	58	41	35
Shares Change (YoY)	8.33%	42.00%	38.79%	17.57%	42.60%
EPS (Basic)	-1.28	-3.36	-1.96	-1.42	-1.41
EPS (Diluted)	-1.28	-3.36	-1.96	-1.42	-1.41
Free Cash Flow	-73.47	-251.44	-117.59	-90.62	-58.42
Free Cash Flow Per Share	-0.83	-3.08	-2.04	-2.19	-1.66
Gross Margin	-43.89%	-	-	-75.80%	-108.15%
Operating Margin	-72.84%	-4671.07%	-574.85%	-122.72%	-179.91%
Profit Margin	-51.99%	-3921.10%	-483.05%	-115.17%	-178.10%
Free Cash Flow Margin	-33.59%	-3592.01%	-502.85%	-177.92%	-209.09%
EBITDA	-156.61	-324.59	-131.95	-60.4	-48.54
EBITDA Margin	-71.61%	-	-	-118.59%	-173.73%
D&A For EBITDA	2.7	2.39	2.48	2.1	1.73
EBIT	-159.31	-326.98	-134.43	-62.5	-50.27
EBIT Margin	-72.84%	-	-	-122.72%	-179.91%
Revenue as Reported	218.71	7	23.39	50.93	27.94

Source: S&P Global Market Intelligence. Standard template. Financial Sources.